

1 **Full title:**

2 **Lipid and nucleocapsid N-protein accumulation in COVID-19**
3 **patient lung and infected cells**

4

5

6 Anita E. Grootemaat¹, Sanne van der Niet¹, Edwin R. Scholl¹, Eva Roos², Bernadette Schurink²,
7 Marianna Bugiani², Sara E. Miller³, Per Larsen^{1,2}, Jeannette Pankras^{1,2}, Eric A. Reits¹, Nicole N. van
8 der Wel^{1*}

9 **Contact information**

10 ¹Electron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre
11 AMC, the Netherlands

12 ² Department of Pathology, Amsterdam University Medical Centers (UMC), VU University
13 Amsterdam, Amsterdam, the Netherlands

14 ³Department of Pathology, Duke University Medical Center, Durham, NC, USA

15

16 *Corresponding author: Nicole van der Wel

17 email address: n.n.vanderwel@amsterdamumc.nl

18 **Abstract**

19 The pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
20 global outbreak and prompted an enormous research effort. Still, the subcellular localization of the
21 corona virus in lungs of COVID-19 patients is not well understood. Here, the localization of the
22 SARS-CoV-2 proteins is studied in postmortem lung material of COVID-19 patients and in SARS-
23 CoV-2 infected Vero cells, processed identically. Correlative light and electron microscopy on semi-
24 thick cryo-sections, demonstrated induction of electron-lucent, lipid filled compartments after SARS-
25 CoV-2 infection in both lung and cell cultures. In lung tissue, the non-structural protein 4 and the
26 stable nucleocapsid N-protein, were detected on these novel lipid filled compartments. The induction
27 of such lipid filled compartments and the localization of the viral proteins in lung of patients with fatal
28 COVID-19, may explain the extensive inflammatory response and provide a new hallmark for SARS-
29 Cov-2 infection at the final, fatal stage of infection.

30

31 **Introduction**

32 The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in late 2019 is the
33 third major outbreak of β -coronaviruses in the human population of the past two decennia, together
34 with the smaller outbreaks of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1) in
35 2003 and Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 2012.

36 SARS-CoV-2 belongs to the family *Coronaviridae*, a large family of single-stranded positive-sense
37 RNA ((+)RNA) viruses. The first two-thirds of the genome typically codes for polyproteins that, once
38 processed by proteases, produce non-structural proteins involved in viral replication [1]. The
39 remaining third of the genome consists of four structural proteins: envelope (E), membrane (M),
40 nucleocapsid (N), and spike (S). Coronaviruses are well known for their ability to induce high
41 membrane plasticity in host cells, where the membrane rearrangements lead to the formation of viral
42 replication organelles (ROs) [2–10]. As observed in SARS-CoV-1, MERS-CoV, and the closely
43 related coronavirus murine hepatitis virus (MHV), the ROs consist of convoluted membranes (CMs)
44 that are interconnected with double-membrane vesicles (DMVs) and appear to be continuous with the
45 membranes that constitute the endoplasmic reticulum (ER) [2,11–17]. Elaborate studies using
46 immuno-fluorescence and electron microscopy (EM) techniques demonstrate that DMVs contain
47 double-stranded RNA (dsRNA) which can be used as a marker of (+)RNA virus replication
48 [2,3,18,19]. Taken together, these findings indicate that the RO serves as the replication and
49 transcription site in which the DMVs, may provide a zone safe from detection by the innate immune
50 sensors and degradation by RNA degradation machinery in the host cell [20,21].

51 The formation of DMVs has been shown to be facilitated by coronaviral non-structural proteins (nsps)
52 [22]. Co-expression of three virally encoded transmembrane proteins, namely nsp3, nsp4, and nsp6,
53 has been found to be sufficient for the production of DMVs in SARS-CoV-1 and MERS-CoV where
54 the interactions of nsp3 and nsp4 result in the pairing and curving of membranes, and nsp6 contributes
55 to the production of vesicles [9,10,23]. A recent publication, using cryo-electron tomography (cryo-
56 ET), shows DMVs of SARS-CoV-2 and MHV in a native host cellular environment containing pore

57 complexes that were not found in previous studies using conventional EM methods [18]. Additionally,
58 the publications by Wolff *et al.* 2020 [24] and Klein *et al.* 2020 [17] demonstrate the presence of N-
59 protein in these DMVs.

60 The subcellular localization of the viral proteins and virus particles is based on infections in cultured
61 cells. In patient material, viral proteins have been localized at a cellular level in various organs of
62 COVID-19 patients [25], including human kidney [26], and in lungs of cynomolgus macaques [27].
63 These studies used light microscopy to find regions of interest, and some of the studies subsequently
64 used EM to find virus particles. One of the hurdles to overcome is the correct identification of viral
65 particles in patient material such as lung [12,28–32], kidney [33–39] and other organs reviewed in [6].
66 Recent publications show data on the morphology and size of isolated SARS-CoV-2 particles [40–43]
67 and virus particles in Vero E6 cells [17] with the use of conventional EM and cryo-EM, although this
68 data alone is not always sufficient to recognize viral proteins or virus particles. Bullock *et al.* proposed
69 a set of eight rules for the correct identification of coronaviruses [6]. Following these rules, a closer
70 inspection of 27 articles where supposed SARS-CoV-2 particles in patient-derived samples have been
71 found, revealed that according to Bullock and Miller, only four articles correctly identified virus
72 [6,44–47]. The most common misinterpretations were clathrin-coated vesicles as single SARS-CoV-2
73 particles and endosome-derived multi-vesicular bodies (MVBs) as ROs [6,47].

74 To assist in this identification conundrum, labelling of antibodies directed against specific viral
75 proteins can be of use. In this article, we provide the first insights into the localizations of both
76 structural and non-structural proteins in SARS-CoV-2-infected Vero cells and compare this with
77 identically processed patient samples retrieved during the first wave of SARS-CoV-2 infections using
78 immuno-gold labelling and CLEM.

79

80 **Results**

81 **Immuno-Electron Microscopy on SARS-CoV-2-infected Vero Cells**

82 Since the outbreak of COVID-19, the identification of virus particles using EM in lung has been a
83 heavily debated subject [6,48,49]. Based on the morphology, it is, especially in postmortem material,
84 difficult to discriminate single virus particles from clathrin-coated vesicles, and MVBs have been
85 interpreted as clusters of virus particles. Therefore, we decided to employ immuno-gold labelling,
86 which can be used to decorate (viral) proteins specifically with 10- or 15-nm gold particles to
87 distinguish them from cell organelles. This way, virus particles with M-, N-, or S-protein and the
88 replication complexes with non-structural proteins can be identified by the gold attached to the
89 specific antibodies. To validate whether the antibodies used for recognition of the proteins in FM [50]
90 can be used on patient materials fixed with an extended fixation protocol, we first tested these
91 antibodies on SARS-CoV-2-infected Vero cells. The antibodies were used on uninfected and 24-hour
92 infected Vero cells fixed for 1, 3, and 14 days as we have fixed patient material in a similar manner.
93 Different antibodies against viral proteins were tested (see Materials and Methods), and successful
94 labelling and their subcellular localizations are described.

95 **Characterization of virus particles with N-protein**

96 Immuno-gold labelling of SARS-CoV-1 structural proteins using a mouse anti-SARS-CoV-1-N (46-4)
97 antibody demonstrated that the nucleocapsid protein (N-protein or N) is detected in the cytosol and on
98 virus particles in several subcellular structures (Figs 1, S1) of infected cells. The N-protein can be
99 specifically detected, as no labelling was detected on uninfected cells. Therefore, all N-protein
100 positive, membrane enclosed spherical structures ranging in size from 60 to 120 nm in diameter and
101 with an electron-dense core (e-dense, black) [6,41], are annotated here as virus particles. Note that in
102 cells and tissues stained with osmium and embedded in resin, membranes appear e-dense, whereas
103 using the immuno-EM method on cryo-sections, membranes appear electron-lucent (e-lucent, white)
104 [51]. This is due to the fact that with the immuno-EM method, membranes are not stained, but only

105 surrounding proteins in the cytosol are stained with uranyl acetate. In 24-hour infected Vero cells,
106 small clusters of N-protein can be detected in proximity to double membrane structures, bending
107 around the N-protein cluster similar to that in the cryo-EM sections (Fig S1), [18]. Coronaviruses are
108 known to be a membrane enveloped viruses, mostly detected inside host membrane structures [6,52],
109 and indeed the majority of the virus particles are surrounded by membranes [3,17] (Figs 1A, 1B).
110 Intact viruses are also identified close to the Golgi (Fig S2), inside multi-virus bodies (MViB) (Fig 1A,
111 S1, S3), inside open e-lucent structures (Fig S4). Both spherical and oval shaped virus particles are
112 visible. The size of the virus particles are measured inside MViBs and intracytoplasmic and are
113 categorized as spherical or oval-shaped. All particles are measured at the longest axis of N-protein-
114 positive particles that have a clear membrane and e-dense core present. The average size between the
115 spherical and oval-shaped virus is slightly different, but not statistically significant. Inside MViBs and
116 intracytoplasmic, spherical particles are identical: $87 \text{ nm} \pm 17 \text{ nm}$ versus $108 \pm 27 \text{ nm}$ and 113 ± 28
117 nm for the oval-shaped particles (Table 1). Different EM techniques result in slightly different sizes,
118 being $97 \pm 12 \text{ nm}$ for oval-shaped cryo-EM fixed extracellular SARS-CoV-2 [43] or 99 nm in resin-
119 embedded spherical virus [41]. Thus, in 24-hour infected Vero cells, N-protein-positive virus particles
120 can be detected as spherical 87-nm to 113-nm oval-shaped membrane structures with an e-dense core,
121 present in the cytosol, close to Golgi, or in multi-vesicular structures.

122 **Classification of virus-containing compartments**

123 As the presence of SARS-CoV-2 in multi-vesicular structures in lung is heavily debated [6,48], we
124 studied the presence of lysosomal markers like CD63 in the multi-virus bodies we showed to be N-
125 protein positive (Fig 1, S1, S3). The Vero cell line is a kidney epithelial cell line from African green
126 monkey, but antibodies against human CD63, a glycosylated transmembrane protein containing a
127 putative lysosomal-targeting/internalisation motif, can be detected in multi-lamellar bodies (MLB)
128 which are lysosomal compartments. Only some CD63 label is detected in the multi-vesicular bodies
129 (Fig S3F). Therefore, we propose that the compartments in which the viral N-protein is detected, is not
130 a true lysosome, but rather a multi-virus body. More elaborate studies on different stages of infection

131 and blocking lysosomal acidification combined with immuno-EM have to be performed to determine
132 the role of these MViBs during viral replication.

133 CD63 is also detected on early endosomes but not present on the majority of the e-lucent structures
134 detected in clusters in SARS-CoV-2 infected cells (Fig S4). These structures seem to be induced by
135 the virus infection, as uninfected cells contain larger lipid droplets but not the clustered e-lucent
136 structures of 327 nm +/- 130 nm. High magnification analyses reveal that the e-lucent compartments
137 appear to be filled with lipid like structures (Figs 1, S1B, S4F, S4H), much like we previously
138 described for *Mycobacterium tuberculosis* infected cells [53]. Therefore, Nile red staining was
139 performed on both uninfected and SARS-CoV-2 infected Vero cells, and a clear increase in Nile red
140 signal is observed in infected cells (Fig 2). Indeed, others already demonstrated that lipid accumulation
141 occurs after SARS-CoV-2 infection in Vero cells [54,55]. To prove that the e-lucent compartments
142 detected with EM are Nile red positive and thus lipid-containing compartments, both FM and EM
143 were performed on the same section and combined in a CLEM image (Fig 2C). These CLEM images
144 demonstrate that at least a part of the e-lucent compartments are lipid filled. The structure of these
145 compartments is not identical to lipid droplets (LD), so we used an antibody specific for perilipin-2,
146 which is known to localize in LD [56] to determine if the SARS-CoV-2 induced lipid filled
147 compartments are in fact lipid droplets. Immuno-gold labelling is present on typical LD in uninfected
148 Vero cells but not on the lipid filled compartments detected in SARS-CoV-2 infected cells (Figs 2F
149 and 2G). Based on the absence of both the lysosomal marker CD63 and LD marker perilipin-2, these
150 e-lucent structures are not lysosomes, nor LD but rather novel lipid-filled compartments induced by
151 SARS-CoV-2 infection.

152 **Localisation of M-protein and non-structural proteins nsp4 and nsp13**

153 The localisation of different viral proteins in cultured cells can be used to understand the pathology
154 and replication of SARS-CoV-2 in lung tissue of COVID-19 patients. In infected Vero cells, the same
155 procedures as for N-protein were applied to detect nsp3, but immuno-gold label is very limited, and
156 thus, we conclude that this antibody does still recognize its substrate after 14 days of glutaraldehyde-

157 paraformaldehyde fixation (Table 2). The non-structural proteins nsp4 and nsp13 are detected on
158 vesicles located nearby and attached to the Golgi stacks (Fig S2). The signal of nsp13 is limited to a
159 few gold particles per Golgi stack, and nsp4 is more distinct, but also has some background on
160 mitochondria (Fig S4G). The M-protein abundantly labels Golgi stacks and vesicles around the Golgi.
161 Interestingly, nsp4, nsp13, and M are also detected on MViBs (Fig S3) and at e-lucent lipid filled
162 compartments, while uninfected cells are unlabelled (Figs 1, S4). These structures resemble double
163 membrane vesicles (DMVs) or single membrane vesicles described for MHV, SARS-CoV-1, SARS-
164 CoV-2, and MERS-CoV infected cells [3,5,16–18,23,50]. Single-membrane vesicles are proposed to
165 be derived from the ER-to-Golgi intermediate compartment [57], and play a role in the secretion of
166 virus to be released into extracellular space. With immuno-EM labelling only on some cellular
167 compartments, a double membrane is detected (Fig S4H, blue arrows), which could be explained by
168 the EM-technique used. Rather than performing high pressure fixation and freeze substitution [3] or
169 cryo-EM [17,18], we used conventional fixation to be able to compare Vero cells with lung tissues of
170 COVID-19 patients. It is possible that the double membranes are lost during fixation for immuno-EM,
171 as Snijder et al already demonstrated in 2006 [16]. Another limitation of the immuno-EM is that no
172 clear spike proteins are detected on extracellular virus particles (Fig 3), though conventional sample
173 preparation using osmium staining and embedding does show spikes [11,41] as does cryo-EM [17,18].
174 Extracellular virus particles are immuno-labelled for both N- and M-protein. Interestingly, the
175 majority of the extracellular virus particles are not spherical, but rather oval-shaped. The subcellular
176 localisation of N-, M-protein and nsps in infected Vero cells is summarized in Table 2, and translation
177 of this knowledge to patient material could be essential for understanding COVID-19 pathogenesis in
178 patients. As immuno-localisation with the antibodies against N-, M-protein, and nsp4, are specific and
179 survive glutaraldehyde fixation, these antibodies can be used for analysis of lung tissues.

180 **Immuno-EM on lung of COVID-19 patients**

181 In lung of COVID-19 patients, we searched for the presence of virus and replication organelles using
182 antibodies selected on infected Vero cells. Material of 7 COVID-19 patients from a prospective
183 autopsy cohort study performed at Amsterdam University Medical Centers (UMC) [25] were included.

184 With informed consent from relatives, full body autopsies were performed, and lung material was
185 fixed for EM analysis. Materials were fixed for 1, 3 or 14 days. From those 7 patients, the lung tissues
186 of 2 were too damaged to use for EM due to a postmortem delay. From our previous light microscopy
187 analysis [25], we learned that only in a part of the lung tissue of a COVID-19 patient N-protein can be
188 detected, and virus particles are difficult to find. Thus, in order to find the infected region of interest
189 (ROI), we first performed fluorescence microscopy on sections of tissues processed for EM, so that
190 when we identified a ROI containing viral proteins, EM could be performed (approached as in van
191 Leeuwen et al., 2018). Semi-thick 0,3- μm slices were incubated with antibodies against SARS-CoV-1
192 nsp3, nsp4, nsp13, and structural proteins N-, M-, and S-protein. We focused on areas near small
193 blood vessels and alveolar walls, as our previous LM analysis revealed infected cells present along the
194 alveolar walls. These cells were identified to be pneumocytes, stromal cells in the septa, endothelial
195 cells in the septal capillaries, and alveolar macrophages [25]. Fluorescence microscopy showed that
196 the N-protein (Fig 4) and nsp4 (Fig 5) could be detected. Noteworthy is the higher background for the
197 M antibody and the relatively low labelling for nsp3 and nsp13 (Table 3).

198 Thus, in lung tissue from COVID-19 patients, an ROI was selected by FM using the N-protein
199 antibody. In one patient (patient 64), relatively large clusters of N-protein were detected (Fig 4A)
200 often in a perinuclear region. As in Vero cells (Fig 2), an increase in lipid accumulation, was observed
201 (Figs 4B, 4C). Nile red staining was combined with N-protein labelling, and N-protein and lipid
202 accumulations, localize in the same general areas but did not co-localize at the same subcellular
203 localisation. Control lung material processed identically to COVID-19 patient material and tested for
204 lipid accumulation demonstrated homogeneous background staining. Sections of 150 nm were
205 analysed with both FM and EM and combined (Fig 4D). In line with our CLEM data on the Vero
206 cells, performing CLEM on lung tissue demonstrated that lung tissue also accumulates lipid in e-
207 lucent compartments. Then ultrathin 60-nm cryo-sections were cut, and protein A conjugated to 10-nm
208 gold particles was used to label N-protein.

209 The ultrastructure of the lung tissue is reasonable, given the fact that this is postmortem material and
210 that it is from a patient with COVID-19. The tissue is unlike healthy lung tissue, not ventilated, but

211 instead filled with erythrocytes and packed with inflammatory cells infiltrating the alveolar lumen and
212 inter-alveolar septa. It is not always possible to identify the cell type specially when the nucleus is not
213 present in the 60-nm thin section. N-protein is detected in cells with large e-lucent compartments, with
214 some label found in e-lucent, lipid filled compartments. Only a few spherical single membrane
215 structures with N-protein were detected (Fig 4 inset). These might be virus-like particles, but due to
216 the low labelling (1 gold particle), the on average larger diameter (110 nm), and an atypical
217 localisation in the cytosol, over-interpretation is possible. Nonetheless, large clusters of viruses are not
218 detected. Besides the limited labelling on small round vesicles, N-protein is also present on
219 membranous structures close to e-lucent compartments (Figs 4F, S5). These structures are not present
220 in all patients; from the 7 patients investigated, 2 had clusters of proteins detectable with the SARS-
221 CoV-1 anti N-protein. In patient 64 (patient description in Schurink et al., 2020), relatively large N-
222 protein clusters at the e-lucent compartments were detected (Figs 4F, S5A-D), and smaller clusters are
223 detected in patient 58, albeit at a similar location [on membrane clusters near the e-lucent
224 compartments (Figs S5E, S5F)].

225 Using FM, nsp4 was identified in the same ROI of lung tissue used for detection of N-protein (Fig 5).
226 Cells positive for nsp4 are present in various tissue compartments. Although background labelling is
227 detected, some cells are brightly positive. Immuno-EM demonstrates nsp4 on e-lucent compartments,
228 which are filled with lipid like structures. A small amount of label is detected on mitochondria which
229 should be regarded as background labelling, as this is also present on uninfected Vero cells (Fig S4G).
230 The summary of subcellular viral protein localisation in lung is presented in Table 3 and, compared to
231 the quantity of labelling in Vero cells, less labelling is detected in only limited compartments. The
232 lipid filled compartments, however, are positive for nsp4, and N-protein is accumulated close to these
233 compartments. Like in Vero cells, lysosomal marker CD63 is absent from these compartments and
234 thus the lipid filled compartments in lung are non-lysosomal. To our knowledge, these lipid filled
235 compartments, containing viral proteins nsp4 and N-protein, have not been identified before and need
236 to be further characterized.

237

238 Discussion

239 Since the outbreak commenced, the identification of corona viruses in lung by EM has been debated,
240 and several articles had to be revised [47,59,60]. Experienced Electron Microscopists [6] have
241 summarized these studies and suggest using one of 3 strategies: 1) visualisation of viral
242 morphogenesis, 2) immuno-EM or *in situ* hybridization, or 3) visualization of particles *in situ* in tissue
243 combined with biochemical evidence of viral presence. We chose immuno-EM with gold labelling
244 using already validated antibodies raised against SARS-CoV-1 [50]. Immuno-EM on Vero cells
245 identified the monoclonal anti-SARS-CoV-1-N 46-4 to be the best for the detection of nucleocapsid
246 N-protein. Virus particles were detected in the process of development as denoted by clusters of
247 cytosolic N-protein surrounded by double membranes (Figs 1, S1). Spherical and/or oval virus
248 particles are detected in MViBs, and in membrane clusters in the cell. The spherical virus particles are
249 stable in size (87 ± 17 nm) and the oval-shaped virus particles are slightly larger (108 ± 27 in MViBs
250 and 113 ± 28 nm for intracytoplasmic) than the spherical ones albeit, these variances are not
251 statistically different. It should be noted that in immuno-EM and at 24 hours of infection, 20 % of the
252 virus particles are scored as oval. The functional difference between spherical versus oval-shaped
253 virus particles still has to be discovered but others have demonstrated that the oval or ellipsoidal-
254 shaped virus particles contain more complexes of RNA and N-protein [43].

255 In lung of patients who had a fatal COVID-19 infection, virus-like particles are rarely detected even
256 though the N-protein is detected in close proximity of the viral induced lipid filled compartments. In
257 Vero cells however, N-protein is detected inside virus particles. It is possible that the difference is
258 caused by incomplete fixation of lung or that ultrastructure is deteriorated in postmortem material. The
259 overall ultrastructure of the tissue, however, is acceptable (Figs 4, 5), because the postmortem time
260 was kept to a minimum and lung tissue was fixed within a few hours, during the first wave of COVID-
261 19 infections in the Netherlands. Finally, it is important to note that the magnification of EM makes
262 finding 90-nm sized virus particles in a tissue block of 1×1 mm², extremely difficult. Still, some
263 studies have detected an occasional cell filled with virus-like particles [44–47].

264 Interestingly, our CLEM data (Figs 2 and 4) demonstrated that part of the e-lucent compartments we
265 have detected in Vero cells and in lung of COVID-19 patients are lipid-filled. Lipids are notoriously
266 difficult to fix with glutaraldehyde and paraformaldehyde alone [61], and thus part of the
267 compartments might have lost the lipid content but lipid accumulation in virus induced compartments
268 is extremely interesting. For viruses of the Flaviviridae family, such as the dengue virus, hepatitis C
269 virus and others, lipid accumulation has been shown to be involved in viral replication [62–69]. High
270 resolution EM studies on cryo-preserved MHV infected cells, suggest DMVs to be filled with viral
271 RNA with LD lying next to the DMVs [18]. Also in infected human pulmonary epithelial Calu-3 cells
272 [13] lipid droplets are detected close to the DMVs. Fluorescence microscopy studies have
273 demonstrated lipid accumulations in SARS-CoV-2-infection, in Vero cells [54] and Nardacci et al.,
274 2021, demonstrated that lipid accumulation is specific for SARS-CoV-2 and not for SARS-CoV-1 in a
275 comparative electron microscopy study and established an increase of LD in lungs from deceased
276 COVID-19 patients. Here, using immuno-EM, combined with Fluorescence microscopy, demonstrate
277 an induction of lipid filled compartments and propose the SARS-CoV-2 infection-induced
278 compartments are not LDs, as they are irregular in shape and have a different morphology than
279 spherical perilipin-2 stained LDs. Also the clearly visible membrane (Fig S2), containing
280 transmembrane proteins nsp4 and nsp13, demonstrates that the viral induced lipid-filled compartments
281 are surrounded by a bilayer, while lipid droplets are surrounded by a monolayer of phospholipids.
282 Taken together, SARS-CoV-2 infection induces novel lipid filled compartments, different from LD or
283 endosomes but with viral proteins nsp4 and N-protein.

284 Here we used the SARS-CoV-2 infected Vero cells to determine in which fixation conditions and on
285 which structures we could detect viral proteins, to compare that with lung tissues from patients
286 conserved in the same conditions. We noticed that not all structures present in Vero cells can be
287 detected at the last stage of infection. A virus induced structure that is well described is convoluted
288 membranes, which was detected in Vero cells (Fig. 1B) but not in lung at the final state of infection. In
289 addition, multi-virus bodies were specifically detected in Vero cells and not in lung (Figs 1, S1, S3).
290 The MViBs are different from lysosomal MVBs, based on the fact that the MViBs are not CD63

291 positive and based on the size, morphology and the M- , N-protein labelling detected within the
292 structures. In the lung of patients with fatal COVID-19, no MViBs were detected. Also double
293 membrane vesicles (DMVs), have been described in several EM studies [2,3,5,15–18] but are not so
294 obvious in our immuno-EM images; only a few double membranes were identified surrounding e-
295 lucent compartments (Fig S4, blue arrows), possible due to fixation limitations, as shown before by
296 Snijder *et al.*, 2006 [16]. As double membranes were not recognizable, DMVs were not annotated in
297 this study. Recent comparison of SARS-CoV-2 infected Vero cells versus lung organoids
298 demonstrated that the subcellular trafficking in Vero cells might be different [70] which can explain
299 the presence of MViB in Vero and absence of these organelle in lung. Also the infections stage could
300 be an explanation as we have analysed postmortem material and thus the last stage of the disease.

301 Remarkably, N-protein and nsp4 are detected in lung of patients in the last stage of the disease. It
302 seems unlikely that only these 2 proteins are still produced by active replication of the virus, rather
303 both N-protein and nsp4 are more stable proteins and thus not degraded. The gene encoding the N-
304 protein is conserved and stable, and the N-protein itself is both highly immunogenic and highly
305 expressed during infection [71]. Work on patients with a SARS-CoV-1 infection demonstrated
306 elevated levels of IgG antibodies against N-protein [72] and showed that N-protein is an antigen for T-
307 cell responses, inducing SARS-CoV-1-specific T-cell proliferation and cytotoxic activity [73–75].
308 Also, in an increasing number of case studies, anti-N IgGs were detected in patients with severe
309 COVID-19 [76] and in children, 5 out of 6 produced neutralizing IgG and IgM antibodies targeted to
310 the N- and S-proteins of SARS-CoV-2 [77]. Interestingly, recent reports show that immune responses
311 to the N-protein have been associated to poor clinical out-comes [78] and correlates with severity of
312 COVID-19 [79].

313 In the current electron microscopy study, we detected in fatal COVID-19 infections using SARS-CoV-
314 specific antibodies, the stable presence of N-protein and nsp4 on novel lipid filled compartments.
315 Already, it has been demonstrated pharmacological inhibition via a key enzyme for LD formation
316 effected SARS-CoV2 replication cells [52] suggesting that lipid accumulation is a potential drug
317 target. The identification of the lipid filled compartments could serve as a hallmark for SARS-CoV-2

318 infections, especially since finding virus particles is challenging. Also we speculate that lipid-filled
319 viral protein-containing compartments play an important role in the secondary effects of the disease.
320 The uncontrolled immune responses causing the devastating damage of COVID-19 likely is
321 responding to either the proteins or even lipids accumulating in these novel subcellular compartments
322 and thus reducing lipid accumulation, will provide new therapeutic strategies.

323 **Materials and Methods**

324 **EM Infection and fixation of Cultured Vero Cells**

325 Vero E6 were seeded (2.5×10^6 cells/T75 flask) one day before infection in MEM/25mM HEPES/2%
326 fetal calf serum with penicillin and streptomycin. Cells ($\sim 5 \times 10^6$ cells/T75) were infected with
327 MOI=0.2 by adding the virus (nCoV-2019/Melb-1, 4.3×10^6 pfu/ml) to each T75 flask. Incubation was
328 performed at 37°C for 24 hours. Then cells with and, as a control without virus, were fixed in 1 part
329 medium plus 1 part 6% PFA + 0,4% GA in 0,4M PHEM buffer (240mM Pipes, 100mM HEPES, 8mM
330 $MgCl_2$ and 40mM EGTA at pH 6.9). After 1, 3 and 14 days of fixation samples were transferred to
331 storage buffer (0,2M PHEM with 0,5% PFA).

332

333 **Collection and initial fixation of tissue from COVID-19 patients**

334 Autopsies were performed at Amsterdam University Medical Centers (UMC), at the VU Medical
335 Center, and the Academic Medical Center, the Netherlands, according to the declaration of Helsinki.
336 For this EM study, 7 patients with clinically confirmed COVID-19 for whom autopsy was requested,
337 were included (Table 4). Ethical approval was granted by the institutional review board of Amsterdam
338 UMC (METC 2020.167). As described by Schurink et al., 2020 COVID-19 was confirmed by
339 quantitative real-time RT-PCR, and informed consent was obtained from the decedents' next of kin.
340 During autopsy, lungs for conventional EM were fixed in Karnovski fixative with 4% PFA with 1%

341 GA in 0,1 M sodium cacodylate buffer. To avoid safety problems, samples were fixed for 14 days and
342 transferred to storage buffer or embedded in gelatin and snap frozen.

343 **Embedding and sectioning**

344 After fixation, cells and tissue were washed 3 times with phosphate buffered saline (PBS) + 0.02M
345 glycine (Merck, K27662101) to remove fixative. Cells were pelleted by centrifugation at 980 xg for 3
346 minutes. Supernatant was removed, and cells were directly embedded in 12% gelatin (Sigma, G2500-
347 500G) in 0.1 M phosphate buffer and pelleted by centrifugation for 3 minutes at 10,950 xg and
348 solidified on ice, and blocks of ~1 mm² were cut with a razor blade. Lung tissue was cut into blocks of
349 1-2 mm² and imbedded in a gelatin series of 2%, 6%, and 12% gelatin in 0.1 M phosphate buffer.
350 Blocks of cells or tissue were incubated overnight in 2.3M sucrose at 4°C (Merck, K17687153) in
351 0.1M phosphate buffer. Then samples were snap frozen and stored in liquid nitrogen. Sectioning was
352 performed using a diamond knife (Diatome cryo-immuno) on a Leica Ultracut UC6 cryo-
353 ultramicrotome. Semi thin sections (150-300 nm) were made at -80°C, and ultrathin sections were
354 made at -120°C. The sections were transferred to a formvar-coated copper grid, gold finder grid, or
355 glass slide in a droplet of 1 part 2% methylcellulose (Sigma, M6385-250G) to 1 part 2.3M sucrose.
356 Sections were stored at 4°C until labelling.

357 **Immuno-fluorescence labelling**

358 Semi-thin cryo-sections were transferred to gold finder grids for EM or to glass slides for light
359 microscopy (LM) and washed with PBS + 0.02M glycine. Then, for LM, semi-thin sections were
360 incubated on primary antibody for 1 hour in PBS + 0.1% bovine serum albumin (Sigma, A4503-50G)
361 and washed with PBS + 0.02M glycine. Thereafter, they were incubated with secondary antibody
362 conjugated to Alexa 488 (Mol. Probes, A32731), and in the last 5 minutes, Nile red (Sigma, 72485)
363 and Hoechst 33342 (Thermo Fisher, H3570) was added. After washing with PBS, a cover slip was
364 mounted with Vectashield (Vector laboratories, H-1000). Glass slides were imaged using a Leica
365 DM6 widefield microscope with a 100x oil objective. Images were analyzed using ImageJ FIJI.

366 **Immuno-gold labelling**

367 For EM, ultrathin sections were picked up and placed on 150 mesh copper grids and incubated on 2%
368 gelatin in 0.1M phosphate buffer for 30 minutes at 37°C. Then, at room temperature, grids were
369 washed with PBS + 0.02M glycine and blocked with 1% BSA in PBS. Grids were incubated with
370 primary antibody in 1% BSA in PBS for 45 minutes. Then, grids were washed with PBS + 0.02M
371 glycine. When the primary antibody was an unlabeled mouse monoclonal antibody, a secondary
372 antibody, raised against mouse serum was used as a bridge to enhance labelling, followed by
373 incubation with protein A conjugated with colloidal gold. In this case, background blocking was done
374 by 0.1% BSA in PBS + 0.02M glycine, followed by incubation on rabbit anti mouse antibody (Z0259,
375 DAKO) for 20 minutes and washed with PBS + 0.02M glycine. Again, grids were incubated in
376 blocking solution and subsequently with protein A conjugated to 10-nm gold (Utrecht University).
377 After washing with PBS, grids were incubated with 1% glutaraldehyde in PBS to fix the antibody-gold
378 complex and washed 10 times for 2 minutes each with water. To contrast the samples, grids were
379 incubated with uranyl acetate in 2% methylcellulose for 5 minutes, and the excess liquid was blotted
380 from the grids with filter paper. Grids were imaged using a FEI Tecnai 120kV transmission electron
381 microscope with a Veleta or Xarosa camera (EMSIS). Images were analyzed using imageJ FIJI.

382 **Correlative light and electron microscopy**

383 For CLEM, we used a method described earlier [58]. In short; grids were washed with PBS + 0.02M
384 glycine and incubated for 1 hour with primary antibody and again washed with PBS + 0.02M glycine.
385 Thereafter, grids were incubated with secondary antibody Alexa 488 and in the last 5 minutes Nile red
386 (Sigma, 72485) and Hoechst 33342 (Thermo Fisher, H3570) were added. After washing in PBS, the
387 grids were mounted in between a glass slide and a coverslip in a droplet of Vectashield. CLEM
388 samples were imaged on a Leica DM6 widefield microscope using a 100x oil objective. Images were
389 analyzed using LasX. After widefield imaging, the coverslip was removed from the glass slide by
390 pipetting PBS in between the coverslip and the glass slide. Vectashield was removed by washing the

391 grid with milliQ water at 37°C. Thereafter, the grids were contrasted and imaged as described above.

392 The correlation was performed using ICY eC-CLEM software.

393 **List of materials:**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit polyclonal anti-Nsp3	kind gift from Snijder laboratory	Leiden University Medical Centre; [16]
Rabbit polyclonal anti-Nsp4	kind gift from Snijder laboratory	Leiden University Medical Centre; [78]
Rabbit polyclonal anti-Nsp13	kind gift from Snijder laboratory	Leiden University Medical Centre; [16]
Rabbit polyclonal anti-M	kind gift from Snijder laboratory	Leiden University Medical Centre; [16]
Rabbit polyclonal anti-N anti-SARS-CoV-1-N (46-4)	kind gift from Snijder laboratory	Leiden University Medical Centre; [80]
Rabbit polyclonal anti-N	Sino Biological Inc	Cat#40143-T62
Monoclonal Mouse Recombinant SARS-CoV anti-N	Sino Biological Inc	Cat#40143-MM05
Mouse monoclonal anti-CD63	Santa Cruz	Cat#MX 49.129.5;RRID11817
Mouse monoclonal anti-Perilipin-2	Progen	Cat#610102;RRID00300-05
Rabbit Bridging anti mouse	DAKO	Cat#Z0259;RRID20007985
Goat anti mouse alexa488	Life technologies	Car#A21242; RRID1345066
Goat anti rabbit alexa488	Mol. Probes, Invitrogen	Cat#A27034;RRID2031072
Protein A conjugated to 10-nm gold	Utrecht University	www.cmc-utrecht.nl
Chemicals		
Nile red	Sigma-Aldrich	72485
Hoechst 33342	Thermo Fisher	H3570
Phosphate buffered saline	Gibco	18912-014
Glycine	Merck	K27662101
Gelatin	Sigma-Aldrich	G2500-500G; CAS9000-70-8
Methylcellulose	Sigma-Aldrich	M6385-250G; CAS9004-67-5
Bovine Serum Albumin	Sigma-Aldrich	A4503-50G; CAS9048-46-8
Vectashield	Vector Laboratories	H-1000
Uranyl acetate	EMS	22400
Virus strains		
nCoV-2019/Melb-1	kind gift from Snijder laboratory	
Experimental Models: Cell Lines		
Vero-cells	kind gift from Snijder laboratory	

394

395

396 **Acknowledgements**

397 We like to thank Eric Snijder, Montse Barcena for input, discussion and providing SARS-CoV-2
398 infected Vero cells, Sabine Krom and Jordy de Bakker for technical assistance, Sandrine Florquin for
399 providing control lung materials; ER, MB thank Funding Amsterdam UMC Corona Research Fund;
400 SvdN was funded by NADP and NIH grant no. AI116604.

401 **References**

- 402 1. Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinares PDB, et al. Structural
403 Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription
404 Complex. *Cell*. Elsevier Inc.; 2020;182: 1560–1573.e13. doi:10.1016/j.cell.2020.07.033
- 405 2. Knoops K, Kikkert M, Van Den Worm SHE, Zevenhoven-Dobbe JC, Van Der Meer Y, Koster
406 AJ, et al. SARS-coronavirus replication is supported by a reticulovesicular network of
407 modified endoplasmic reticulum. *PLoS Biol*. 2008;6: 1957–1974.
408 doi:10.1371/journal.pbio.0060226
- 409 3. Snijder EJ, Limpens RWAL, de Wilde AH, de Jong AWM, Zevenhoven-Dobbe JC, Maier HJ,
410 et al. A unifying structural and functional model of the coronavirus replication organelle:
411 Tracking down RNA synthesis. *bioRxiv*. 2020; doi:10.1101/2020.03.24.005298
- 412 4. Maier HJ, Hawes PC, Cottam EM, Mantell J, Verkade P, Monaghan P, et al. Infectious
413 bronchitis virus generates spherules from zippered endoplasmic reticulum membranes. *MBio*.
414 2013;4: 1–12. doi:10.1128/mBio.00801-13
- 415 5. Ulasli M, Verheije MH, de Haan CAM, Reggiori F. Qualitative and quantitative ultrastructural
416 analysis of the membrane rearrangements induced by coronavirus. *Cell Microbiol*. 2010;12:
417 844–861. doi:10.1111/j.1462-5822.2010.01437.x
- 418 6. Bullock HA, Goldsmith CS, Miller SE. Best practices for correctly identifying coronavirus by
419 transmission electron microscopy. *Kidney Int*. Elsevier Inc; 2021;99: 824–827.
420 doi:10.1016/j.kint.2021.01.004
- 421 7. Den Boon JA, Ahlquist P. Organelle-like membrane compartmentalization of positive-strand
422 RNA virus replication factories. *Annu Rev Microbiol*. 2010;64: 241–256.
423 doi:10.1146/annurev.micro.112408.134012
- 424 8. Romero-Brey I, Bartenschlager R. Endoplasmic reticulum: The favorite intracellular niche for

- 425 viral replication and assembly. *Viruses*. 2016;8: 1–26. doi:10.3390/v8060160
- 426 9. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory
427 syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles.
428 *MBio*. 2013;4: 1–10. doi:10.1128/mBio.00524-13
- 429 10. Angelini MM, Neuman BW, Buchmeier MJ. Untangling membrane rearrangement in the
430 nidovirales. *DNA Cell Biol*. 2014;33: 122–127. doi:10.1089/dna.2013.2304
- 431 11. Eymieux S, Rouillé Y, Terrier O, Seron K, Blanchard E, Rosa-Calatrava M, et al.
432 Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral
433 factory formation, viral particle morphogenesis and virion release. *Cell Mol Life Sci*. Springer
434 International Publishing; 2021;78: 3565–3576. doi:10.1007/s00018-020-03745-y
- 435 12. Yao XH, He ZC, Li TY, Zhang HR, Wang Y, Mou H, et al. Pathological evidence for residual
436 SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. *Cell Res*. Springer US;
437 2020;30: 541–543. doi:10.1038/s41422-020-0318-5
- 438 13. Cortese M, Lee JY, Cerikan B, Neufeldt CJ, Oorschot VMJ, Köhrer S, et al. Integrative
439 Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies. *Cell Host
440 Microbe*. 2020;28: 853–866.e5. doi:10.1016/j.chom.2020.11.003
- 441 14. Hagemeyer MC, Ulasli M, Vonk AM, Reggiori F, Rottier PJM, de Haan CAM. Mobility and
442 Interactions of Coronavirus Nonstructural Protein 4. *J Virol*. 2011;85: 4572–4577.
443 doi:10.1128/jvi.00042-11
- 444 15. Mihelc EM, Baker SC, Lanman JK. Coronavirus infection induces progressive restructuring of
445 the endoplasmic reticulum involving the formation and degradation of double membrane
446 vesicles. *Virology*. Elsevier Inc.; 2021;556: 9–22. doi:10.1016/j.virol.2020.12.007
- 447 16. Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJM, van der Meulen J, Koerten
448 HK, et al. Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute
449 Respiratory Syndrome Coronavirus Replication Complex. *J Virol*. 2006;80: 5927–5940.

- 450 doi:10.1128/jvi.02501-05
- 451 17. Klein S, Cortese M, Winter SL, Wachsmuth-Melm M, Neufeldt CJ, Cerikan B, et al. SARS-
452 CoV-2 structure and replication characterized by in situ cryo-electron tomography. *Nat*
453 *Commun.* Springer US; 2020;11: 1–10. doi:10.1038/s41467-020-19619-7
- 454 18. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM, et al.
455 A molecular pore spans the double membrane of the coronavirus replication organelle. *Science*
456 (80-). 2020;369: 1395–1398. doi:10.1126/SCIENCE.ABD3629
- 457 19. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC. RNA Replication of Mouse
458 Hepatitis Virus Takes Place at Double-Membrane Vesicles. *J Virol.* 2002;76: 3697–3708.
459 doi:10.1128/jvi.76.8.3697-3708.2002
- 460 20. Shulla A, Randall G. (+) RNA virus replication compartments: a safe home for (most) viral
461 replication. *Curr Opin Microbiol.* 2016;32: 82–88.
- 462 21. Scutigliani EM, Kikkert M. Interaction of the innate immune system with positive-strand RNA
463 virus replication organelles. *Cytokine Growth Factor Rev.* 2017;37: 17–27.
- 464 22. Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, et al. The M, E, and N Structural
465 Proteins of the Severe Acute Respiratory Syndrome Coronavirus Are Required for Efficient
466 Assembly, Trafficking, and Release of Virus-Like Particles. *J Virol.* 2008;82: 11318–11330.
467 doi:10.1128/jvi.01052-08
- 468 23. Oudshoorn D, Rijs K, Limpens RWAL, Groen K, Koster AJ, Snijder EJ, et al. Expression and
469 cleavage of middle east respiratory syndrome coronavirus nsp3-4 polyprotein induce the
470 formation of double-membrane vesicles that mimic those associated with coronaviral RNA
471 replication. *MBio.* 2017;8: 1–17. doi:10.1128/mBio.01658-17
- 472 24. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM, et al.
473 A molecular pore spans the double membrane of the coronavirus replication organelle.
474 bioRxiv. 2020;1398: 1395–1398. doi:10.1101/2020.06.25.171686

- 475 25. Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. Viral presence and
476 immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. *The*
477 *Lancet Microbe*. 2020;1: e290–e299. doi:10.1016/s2666-5247(20)30144-0
- 478 26. Ng JH, Bijol V, Sparks MA, Sise ME, Izzedine H, Jhaveri KD. Pathophysiology and Pathology
479 of Acute Kidney Injury in Patients With COVID-19. *Adv Chronic Kidney Dis*. Elsevier Inc;
480 2020;27: 365–376. doi:10.1053/j.ackd.2020.09.003
- 481 27. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, de Meulder D, et al. Comparative
482 pathogenesis of COVID-19, MERS and SARS in a non-human primate model. *Science* (80-).
483 2020;368: 1012–1015. doi:10.1101/2020.03.17.995639
- 484 28. Pesaresi M, Pirani F, Tagliabracci A, Valsecchi M, Procopio AD, Busardò FP, et al. SARS-
485 CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning
486 electron microscopy. *Eur Rev Med Pharmacol Sci*. 2020;24: 5186–5188.
487 doi:10.26355/eurev_202005_21217
- 488 29. Grimes Z, Bryce C, Sordillo EM, Gordon RE, Reidy J, Paniz Mondolfi AE, et al. Fatal
489 Pulmonary Thromboembolism in SARS-CoV-2-Infection. *Cardiovasc Pathol*. 2020;48:
490 107227. doi:10.1016/j.carpath.2020.107227
- 491 30. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary
492 Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med*. 2020;383:
493 120–128. doi:10.1056/nejmoa2015432
- 494 31. Borczuk AC, Salvatore SP, Seshan S V., Patel SS, Bussel JB, Mostyka M, et al. COVID-19
495 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. *Mod*
496 *Pathol*. Springer US; 2020;33: 2156–2168. doi:10.1038/s41379-020-00661-1
- 497 32. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and
498 ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. *Lacet*.
499 2020;396: 320–332.

- 500 33. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26
501 postmortem findings of patients with COVID-19 in China. *Kidney*. 2020;98: 219–227.
- 502 34. Kissling S, Rotman S, Gerber C, Halfon M, Lamoth F, Comte D, et al. Collapsing
503 glomerulopathy in a COVID-19 patient. *Kidney Int*. 2020;98: 228–231.
504 doi:10.1016/j.kint.2020.04.006
- 505 35. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
506 Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. Elsevier Ltd; 2020;395:
507 1417–1418. doi:10.1016/S0140-6736(20)30937-5
- 508 36. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with
509 sars-cov-2. *J Am Soc Nephrol*. 2020;31: 1683–1687. doi:10.1681/ASN.2020040432
- 510 37. Abbate M, Rottoli D, Gianatti A. Covid-19 attacks the kidney: Ultrastructural evidence for the
511 presence of virus in the glomerular epithelium. *Nephron*. 2020; doi:10.1159/000508430
- 512 38. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Postmortem
513 examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary
514 congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.
515 *Histopathology*. 2020;77: 198–209. doi:10.1111/his.14134
- 516 39. Werion A, Belkhir L, Perrot M, Schmit G, Aydin S, Chen Z, et al. SARS-CoV-2 causes a
517 specific dysfunction of the kidney proximal tubule. *Kidney Int*. 2020;98: 1296–1307.
- 518 40. Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, et al. Structures and distributions of
519 SARS-CoV-2 spike proteins on intact virions. *Nature*. Springer US; 2020;588: 498–502.
520 doi:10.1038/s41586-020-2665-2
- 521 41. Laue M, Kauter A, Hoffmann T, Möller L, Michel J, Nitsche A. Morphometry of SARS-CoV
522 and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures
523 Michael. *Sci Rep*. 2021;11.

- 524 42. Turoňová B, Sikora M, Schürmann C, Hagen WJH, Welsch S, Blanc FEC, et al. In situ
525 structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. *bioRxiv*.
526 2020;208: 203–208. doi:10.1101/2020.06.26.173476
- 527 43. Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, et al. Molecular Architecture of the SARS-CoV-
528 2 Virus. *Cell*. Elsevier Inc.; 2020;183: 730–738.e13. doi:10.1016/j.cell.2020.09.018
- 529 44. Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, et al. Pathology and
530 pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, united states. *Emerg*
531 *Infect Dis*. 2020;26: 2005–2015. doi:10.3201/eid2609.202095
- 532 45. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-
533 mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive
534 study. *Lancet infect dis*. 2020;20: 1135–1140.
- 535 46. Falasca L, Nardacci R, Colombo D, Lalle E, DI Caro A, Nicastri E, et al. Postmortem Findings
536 in Italian Patients with COVID-19: A Descriptive Full Autopsy Study of Cases with and
537 without Comorbidities. *J Infect Dis*. 2020;222: 1807–1815. doi:10.1093/infdis/jiaa578
- 538 47. Dittmayer C, Meinhardt J, Radbruch H, Radke J, Heppner BI, Heppner FL, et al. Why
539 misinterpretation of electron micrographs in SARS-CoV-2-infected tissue goes viral. *Lancet*.
540 Elsevier Ltd; 2020;396: e64–e65. doi:10.1016/S0140-6736(20)32079-1
- 541 48. Goldsmith CS, Miller SE, Martines RB, Bullock HA, Zaki SR. Electron microscopy of SARS-
542 CoV-2: a challenging task. *Lancet*. Elsevier Ltd; 2020;395: e99. doi:10.1016/S0140-
543 6736(20)31188-0
- 544 49. Akilesh S, Nicosia RF, Alpers CE, Tretiakova M, Hsiang TY, Gale M, et al. Characterizing
545 Viral Infection by Electron Microscopy: Lessons from the Coronavirus Disease 2019
546 Pandemic. *Am J Pathol*. American Society for Investigative Pathology; 2021;191: 222–227.
547 doi:10.1016/j.ajpath.2020.11.003
- 548 50. Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L,

- 549 et al. SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation
550 and cytopathology. *J Gen Virol.* 2020;101: 925–940. doi:10.1099/jgv.0.001453
- 551 51. van der Wel NN, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, et al. M . tuberculosis
552 and M . leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells. *Cell.*
553 2007; 1287–1298. doi:10.1016/j.cell.2007.05.059
- 554 52. Bullock HA, Goldsmith CS, Zaki SR, Martines RB, Miller SE. Difficulties in differentiating
555 coronaviruses from subcellular structures in human tissues by electron microscopy. *Emerg*
556 *Infect Dis.* 2021;27: 1023–1031. doi:10.3201/eid2704.204337
- 557 53. Buter J, Cheng T-Y, Ghanem M, Grootemaat AE, Raman S, Feng X, et al. Mycobacterium
558 tuberculosis releases an antacid that remodels phagosomes. *Nat Chem Biol.* Springer US;
559 2019;15: 889–899. doi:10.1038/s41589-019-0336-0
- 560 54. da Silva Gomes Dias S, Soares VC, Ferreira AC, Sacramento CQ, Fintelman-Rodrigues N,
561 Temerozo JR, et al. Lipid droplets fuel SARS-CoV-2 replication and production of
562 inflammatory mediators. *PLoS Pathog.* 2020;16: 1–19. doi:10.1371/journal.ppat.1009127
- 563 55. Nardacci R, Colavita F, Castilletti C, Lapa D, Matusali G, Meschi S, et al. Evidences for lipid
564 involvement in SARS-CoV-2 cytopathogenesis. *Cell Death Dis.* Springer US; 2021;12.
565 doi:10.1038/s41419-021-03527-9
- 566 56. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a
567 major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of
568 lipid storage droplets. *J Biol Chem.* © 1991 ASBMB. Currently published by Elsevier Inc;
569 originally published by American Society for Biochemistry and Molecular Biology.; 1991;266:
570 11341–11346. doi:10.1016/s0021-9258(18)99168-4
- 571 57. de Haan CAM, Rottier PJM. Molecular Interactions in the Assembly of Coronaviruses. *Adv*
572 *Virus Res.* 2005;64: 165–230. doi:10.1016/S0065-3527(05)64006-7
- 573 58. van Leeuwen LM, Boot M, Kuijl C, Picavet DI, van Stempvoort G, van der Pol SMA, et al.

- 574 Mycobacteria employ two different mechanisms to cross the blood–brain barrier. *Cell*
575 *Microbiol.* 2018;20: 1–17. doi:10.1111/cmi.12858
- 576 59. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, Duarte-Neto AN, Soares Gomes-
577 Gouvêa M, Viu Degaspere N, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-
578 related multisystem inflammatory syndrome. *Lancet Child Adolesc Heal.* 2020;4: 790–794.
579 doi:10.1016/S2352-4642(20)30257-1
- 580 60. Kniss DA. Alternative interpretation to the findings reported in visualization of severe acute
581 respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy.
582 *Am J Obstet Gynecol.* Elsevier Inc.; 2020;223: 785–786. doi:10.1016/j.ajog.2020.06.016
- 583 61. Fujimoto T, Ohsaki Y, Suzuki M, Cheng J. Imaging Lipid Droplets by Electron Microscopy.
584 *Methods in Cell Biology.* 1st ed. Elsevier Inc.; 2013. pp. 227–251. doi:10.1016/B978-0-12-
585 408051-5.00012-7
- 586 62. Villareal VA, Rodgers MA, Costello DA, Yang PL. Targeting host lipid synthesis and
587 metabolism to inhibit dengue and hepatitis C viruses. *Antiviral Res.* 2015;124: 110–121.
588 doi:10.1016/j.antiviral.2015.10.013.Targeting
- 589 63. Lyn RK, Hope G, Sherratt AR, McLauchlan J, Pezacki JP. Bidirectional lipid droplet velocities
590 are controlled by differential binding strengths of HCV core DII protein. *PLoS One.* 2013;8.
591 doi:10.1371/journal.pone.0078065
- 592 64. Filipe A, McLauchlan J. Hepatitis C virus and lipid droplets: Finding a niche. *Trends Mol Med.*
593 Elsevier Ltd; 2015;21: 34–42. doi:10.1016/j.molmed.2014.11.003
- 594 65. Cheung W, Gill M, Esposito A, Kaminski CF, Courousse N, Chwetzoff S, et al. Rotaviruses
595 Associate with Cellular Lipid Droplet Components To Replicate in Viroplasms, and
596 Compounds Disrupting or Blocking Lipid Droplets Inhibit Viroplasm Formation and Viral
597 Replication. *J Virol.* 2010;84: 6782–6798. doi:10.1128/jvi.01757-09
- 598 66. Coffey CM, Sheh A, Kim IS, Chandran K, Nibert ML, Parker JSL. Reovirus Outer Capsid

- 599 Protein μ 1 Induces Apoptosis and Associates with Lipid Droplets, Endoplasmic Reticulum, and
600 Mitochondria. *J Virol.* 2006;80: 8422–8438. doi:10.1128/jvi.02601-05
- 601 67. Samsa MM, Mondotte JA, Iglesias NG, Assunção-Miranda I, Barbosa-Lima G, Da Poian AT,
602 et al. Dengue virus capsid protein usurps lipid droplets for viral particle formation. *PLoS*
603 *Pathog.* 2009;5. doi:10.1371/journal.ppat.1000632
- 604 68. Ilnytska O, Santiana M, Hsu N, Du W, Chen Y, Viktorova EG, et al. Enteroviruses harness the
605 cellular endocytic machinery to remodel the host cell cholesterol landscape for effective viral
606 replication. *Cell Host Microbe.* 2013;14: 281–293.
607 doi:10.1016/j.chom.2013.08.002. Enteroviruses
- 608 69. Melia CE, Peddie CJ, de Jong AWM, Snijder EJ, Collinson LM, Koster AJ, et al. Origins of
609 enterovirus replication organelles established by whole-cell electron microscopy. *MBio.*
610 2019;10: 1–12. doi:10.1128/mBio.00951-19.
- 611 70. Beumer J, Geurts MH, Lamers MM, Puschhof J, Zhang J, Der J Van. A CRISPR / Cas9
612 genetically engineered organoid biobank reveals essential host factors for coronaviruses.
613 bioRxiv. 2021;
- 614 71. Cong Y, Ulasli M, Schepers H, Mauthe M, V'kovski P, Kriegenburg F, et al. Nucleocapsid
615 Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in
616 Coronaviral Life Cycle. *J Virol.* 2020;94: 1–21. doi:10.1128/jvi.01925-19
- 617 72. Leung DTM, Tam FCH, Chun HM, Chan PKS, Cheung JLK, Niu H, et al. Antibody response
618 of patients with Severe Acute Respiratory Syndrome (SARS) targets the viral nucleocapsid. *J*
619 *Infect Dis.* 2004;190: 379–386. doi:10.1086/422040
- 620 73. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for
621 Vaccine Development. *J Virol.* 2020;94: 1–2. doi:10.1128/jvi.00647-20
- 622 74. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response
623 During SARS-CoV-2 Infection: Lessons From the Past. *Front Immunol.* 2020;11: 1–17.

- 624 doi:10.3389/fimmu.2020.01949
- 625 75. Gao W, Tamin A, Soloff A, Aiuto LD, Nwanegbo E, Robbins PD, et al. Effects of a SARS-
626 associated coronavirus vaccine in monkeys. *Lancet*. 2003;362: 1895–1896.
- 627 76. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of
628 viral load in posterior oropharyngeal saliva samples and serum antibody responses during
629 infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. Elsevier Ltd;
630 2020;20: 565–574. doi:10.1016/S1473-3099(20)30196-1
- 631 77. Zhang Y, Xu J, Jia R, Yi C, Gu W, Liu P, et al. Protective humoral immunity in SARS-CoV-2
632 infected pediatric patients. *Cell Mol Immunol*. Springer US; 2020;17: 768–770.
633 doi:10.1038/s41423-020-0438-3
- 634 78. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early Serological
635 Signatures Track with SARS-CoV-2 Survival. *Immunity*. Elsevier Inc.; 2020;53: 524–532.e4.
636 doi:10.1016/j.immuni.2020.07.020
- 637 79. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of
638 COVID-19 patients reveals cross-reactivity and correlates of severity. *Science* (80-).
639 2020;370. doi:10.1126/science.abd4250
- 640 80. Fang Y, Pekosz A, Haynes L, Nelson EA, Rowland RRR. Production and characterization of
641 monoclonal antibodies against the nucleocapsid protein of SARS-CoV. *Adv Exp Med Biol*.
642 2006;581: 153–156. doi:10.1007/978-0-387-33012-9_27
- 643 81. Casasanta MA, Jonaid GM, Kaylor L, Luqiu WY, Solares MJ, Schroen ML, et al. Microchip-
644 based structure determination of low-molecular weight proteins using cryo-electron
645 microscopy. *Nanoscale*. Royal Society of Chemistry; 2021;13: 7285–7293.
646 doi:10.1039/d1nr00388g
- 647 82. Moriel-Carretero M. The hypothetical role of phosphatidic acid in subverting ER membranes
648 during SARS-CoV infection. *Traffic*. 2020;21: 545–551. doi:10.1111/tra.12738

649 83. Van Hemert MJ, Van Den Worm SHE, Knoops K, Mommaas AM, Gorbalenya AE, Snijder EJ.
650 SARS-coronavirus replication/transcription complexes are membrane-protected and need a
651 host factor for activity in vitro. PLoS Pathog. 2008;4. doi:10.1371/journal.ppat.1000054

652

653

654 **Tables**

655

Location	MViB		Intracytoplasmic	
Virus shape	spherical	oval	spherical	oval
x in nm	87±17	108±27	87±17	113±28
n	61	21	59	8

656 **Table 1. Average particle size at different subcellular locations.** Average size of virus particles in
 657 multi-virus bodies (MViB), and intracytoplasmic was measured and presented as average size (x) ±
 658 standard deviation and number of virus particles measured (n) in Vero cells infected with SARS-CoV-
 659 2 for 24 hours and immuno-gold labelled for N-protein with 10-nm gold.

660

Location in cell culture	N	M	Nsp3	Nsp4	Nsp13	CD63
Virus particle	+	+	-	-	-	-
Golgi	+/-	+	-	+	+/-	-
MViB	+	+	-	+/-	+/-	+/-
MLB	-	-	-	-	-	+
e-lucent compartment	+/-	+/-	-	+	+/-	-
extracellular virus particle	+	+	-	-	-	-

661 **Table 2. Immuno-gold labelling of viral proteins in SARS-CoV-2-infected Vero cells.** Presence of
 662 immuno-gold labelling on virus particles, Golgi, multi-virus bodies (MViB), multi-lamellar bodies
 663 (MLB), e-lucent compartments and extracellular virus particles in Vero cells infected with SARS-
 664 CoV-2 for 24 hours. Annotations: + present; - absent; +/- present but less prominent.

665

666

Location in lung	N	M	Nsp3	Nsp4	Nsp13	CD63
Virus particle	+/-	-	-	-	-	-
Golgi	-	-	-	-	-	-
MViB	-	-	-	-	-	-
MLB	-	-	-	-	-	+
e-lucent compartment	+/-	+/-	-	+	-	-
Extracellular virus particle	-	-	-	-	-	-

667 **Table 3. Immuno-gold labelling of viral proteins in SARS-CoV-2 infected lung.** Presence of
 668 immuno-gold labelling on virus particles, Golgi, multi-virus bodies (MViB), multi-lamellar bodies
 669 (MLB), e-lucent compartments and extracellular virus particles in patient 58 and 64 infected with
 670 SARS-CoV-2. Annotations: + present; - absent; +/- present but less prominent.

671

Patient	Infection stadium	Sex	Age	COV-N	Remarks
SVU 20-58	Limited infected cells in lung, limited systemic presence (HPB tract)	F	72	+	Data presented
SVU 20-39	Severe infected cells in lungs, systemic presence (GI tract)	M	73	+	
SVU 20-63	No presence in lung, limited presence in the heart	M	74	+	
SVU 20-64	Limited presence in the lung, no systemic presence	F	68	+	Data presented
SVU 20-155	-	F	75	+	
SVU 20-163	-	M	61	+	
SVU 20-174	-	M	78	+	
SVU 20-129	Control non-covid	M	68	-	
T18-5683	Control non-covid	F	5	-	Data presented
T18-10645	Control non-covid	F	15	-	

672 **Table 4. Patient description.** Information of patients from who autopsy material was taken with
 673 informed consent and fixed for electron microscopy. In this study, electron micrographs were used
 674 from patients SVU 20-58, SVU 20-64, and control T18-5683.

675 **Figure Legends**

676 **Figure 1. Subcellular localisation of viral proteins in infected Vero-cells.** Vero cells were infected
677 with SARS-CoV-2 for 24 hours and immuno-EM labelled with antibodies against SARS-CoV-1
678 proteins, followed by secondary antibodies conjugated to 10-nm gold particles. A) Clusters of N-
679 protein labelling in cytosol (open arrows), and (enlarged in A') on double membrane spherules (right-
680 most black arrow), or virus particles enclosed in a single membrane (two left-most black arrows).
681 From the e-lucent compartment (red *) a “virus-like” particle (as it is without N-protein labelling) is
682 budding (white arrow). A'') enlarged area with MViB containing labelled and unlabelled virus-like
683 particles. B) M-protein immuno-gold labelling on e-lucent compartments (gold is circled in red); in
684 enlarged box, immuno-gold labelling on convoluted membrane structure (CM). Note virus-like
685 particles are not labelled. C) Immuno-gold labelling of nsp4 on e-lucent compartments (circled in red)
686 and various virus like particles enclosed in a membrane without nsp4 labelling, also enlarged in C' . D)
687 immuno-labelling of nsp13 on e-lucent compartments containing lipid like structures (red arrows). D')
688 higher magnification of D. Immuno-gold decoration on e-lucent compartments is indicated by red
689 circles; mitochondria by m, multiple virus body by MViB, convoluted membrane structure by CM,
690 lipid like structures by red arrows, N-protein in cytosol by open arrows, N-protein labelled virus by
691 black arrows, and black boxes indicate enlarged area.

692 **Figure 2. Lipid accumulates in e-lucent compartments more densely in infected Vero cells.**
693 Fluorescence microscopy of DNA and lipid staining with Nile red in A) the uninfected control (Con)
694 Vero cells and B) cells infected with SARS-CoV-2 for 24 hours; C) Electron microscopy of infected
695 cells; D) Fluorescence microscopy of the same cells, and E) Correlative light-electron microscopy
696 (CLEM) showing lipid staining at e-lucent compartments in the electron microscope. Immuno-EM
697 labelling for lipid droplet marker perilipin-2 in F) uninfected Vero cells and G) cells infected with
698 SARS-CoV-2 for 24 hours. Blue color in A, B, D, and E shows the nuclei stained with Hoechst and
699 red shows the lipids stained with Nile red. In electron micrographs, lipid like structure is denoted by

700 red arrows, virus particles by black arrows, immuno-gold labelling of perilipin-2 by red circles,
701 mitochondria by m, and lipid droplets by LD.

702 **Figure 3. Release of virus particles from Vero cells infected with SARS-CoV-2 for 24 hr.** EM
703 micrographs, demonstrate A) lack of immuno-gold labelling on extracellular virus particle using anti-
704 nsp4, a non-structural protein of SARS-CoV-2 (black arrow); B) extracellular virus particles labelled
705 with anti-N-protein, and C) anti-M-protein also labels on extracellular virus particles. Here, m
706 represents mitochondrion, MViB multi-virus body.

707 **Figure 4. N-protein in e-lucent compartments in Lung COVID-19 patient.** Lung from control and
708 infected patients was either sectioned semi-thin for FM (A-C) or CLEM (D) and stained with Hoechst
709 (blue) to identify nuclei, Nile red (red) to denote lipid, or anti-N-protein (green) to show N-protein, or
710 it was ultrathin-sectioned for EM (E and F) and immuno-gold labelled using anti N-protein followed
711 by secondary antibody tagged with 10-nm gold particles. A) COVID-19-infected lung showing
712 accumulations of N-protein and Nile red stained lipids. B) overview of an uninfected control lung with
713 no N-protein or lipid accumulation. C) Overview of infected lung with lipid accumulation. Identical
714 section analysed by CLEM of infected lung demonstrate the e-lucent compartments present by EM (D)
715 are Nile red and N-protein labelled (D') by the overlay of the FM on the EM micrograph (D'').
716 Immuno-gold labelling of infected lung with antibody against N-protein at low magnification (E) and
717 magnified region from boxed area where lipid like structures (open red arrows) are visible (E') and a
718 single virus particle with N labelling (E''), low magnification of N-protein labelling on membrane
719 structures near the e-lucent compartments F); high magnification of F') clusters of N-protein labelling.
720 Erythrocytes represented by e, nucleus by n, open red arrow lipid like structures, and boxed areas
721 enlarged region.

722 **Figure 5. Non-structural protein 4 in e-lucent compartments infected lung.** Lung tissue of
723 COVID-19 patient 58 was either sectioned semi-thin for FM with A) nuclei, stained with Hoechst
724 (blue), nsp4 stained with Alexa (green) in nsp4 positive cells indicated by white arrows and in black
725 and white, and erythrocytes represented by e. Separate channels of nsp4 (B) and DNA (C). Ultrathin

726 sections of infected lung immuno-gold labelled against nsp-4 and 10-nm gold particles in overview
727 (D) and at higher magnification (E) e-lucent compartments with nsp4 labelling on membrane and lipid
728 like structures (open red arrows) erythrocytes represented by e. F) Schematic representation of
729 uninfected Vero cells, SARS-CoV-2 infected Vero cells and lung tissue of COVID-19 patient
730 summarizing presence cellular organelles and subcellular localisation viral proteins. In black: host
731 compartments, in green: viral compartments, in pink: lipid like structures, CM convoluted membrane
732 G: Golgi, LD: lipid droplet, MLB: multi-lamellar bodies, MViB: multi-virus body, LFC: lipid-filled
733 compartment and immuno-labelling viral proteins: dark green triangle: nsp13, light green triangle:
734 nsp4, blue circle: N-protein, yellow square: M-protein.

Figure 1






Figure 2


Con Vero: Lipid DNA




SARS-CoV-2 Vero: Lipid DNA



EM



FM: Lipid DNA



CLEM






Figure 3








Figure 4


DNA Lipid N patient 64




DNA Lipid Control patient




DNA Lipid patient 58



EM patient 58



FM DNA Lipid N



CLEM








Figure 5

